NEW YORK & MCLEAN, Va.–(BUSINESS WIRE)–Massive Bio, a leader in recruiting AI-based cancer clinical trials, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with treatment options based on biomarkers. Perthera.ai’s Patented Ranked Treatment Recommendations Complement Massive Bio’s Screening and Analysis to Empower More Cancer Patients to find a suitable clinical trial.
Less than three percent of cancer patients today are matched and enrolled in a clinical trial. By combining the two companies’ advanced computational methods and artificial intelligence capabilities, more physicians and patients will be able to confidently access the benefits of experimental precision oncology treatments from specific, FDA-approved novel therapies. patients’ unique molecular and genetic biomarkers. Perthera.ai combines multi-omics test results (DNA, RNA, IHC and phosphoproteomics) to advise oncologists and their patients and simplify the decision-making process to increase the chances that the best therapy will be used the first time. .
“We are thrilled to partner with Massive Bio to leverage the most advanced science and technology to help as many cancer patients as possible,” said Albert Kelley, CEO of Perthera.ai. “Increasing access to genomic and multi-omics testing and patient-assay matching solutions is the single best way to advance cancer care for all. We believe in collaboration where it can help more patients and by combining our strengths with Massive Bio, we can improve data acquisition and patient-trial matching accuracy.
“Our mission is to create hope and empower cancer patients by helping them find their best treatment options, which often requires access to clinical trials,” said Selin Kurnaz, co- founder and CEO of Massive Bio. “By combining Perthera.ai’s focus on biomarker-based algorithms with our AI-powered clinical trial matching platform, we can create more options for patients and physicians to find the best tests. We can also jointly pursue additional innovations around real-world data, biomarker discovery, and diagnostic and commercial collaborations with industry stakeholders.
Dr. Arturo Loaiza-Bonilla, co-founder and chief medical officer of Massive Bio, added, “We are excited to expand our datasets and leverage our combined technologies and networks to provide more treatment pathways. precise, which will have an immediate and positive impact. impact to identify more treatment options for more patients.
Perthera.ai is a pioneer in using multi-omics test results to advise oncologists and patients on treatment options through our Precision Oncology Platform and the Perthera Report it generates. Perthera.ai collects multi-omics results from any source and uses a patented precision oncology platform to generate ranked treatment options that have been shown to increase survival for patients with breast cancer. pancreas that use highly ranked therapy. Perthera.ai aspires to bring its proprietary technology to as many cancer patients as possible, regardless of location or financial resources.
About Massive Bio:
Massive Bio empowers cancer patients to find their best treatment options, providing convenient access and enrollment services for oncology clinical trials worldwide, powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to cutting-edge therapies, Massive Bio combines its state-of-the-art AI platform with expertise in genomics, engineering and data analytics to break down the many barriers to enrollment and participation of cancer patients. clinical tests. Based in New York, Massive Bio is a private company that operates in 12 countries.